Investors & Media Press Releases
Axovant to Move Stock Exchange Listing to Nasdaq
"Nasdaq is a great fit for Axovant as it is home for leading biotechnology companies and we are honored to now be among them," said
"We are proud to have Axovant join our family of companies where they will now be listed among the world's largest, most influential and disruptive biotechnology companies," said
Axovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to broadly address multiple forms of dementia and related neurological disorders. Axovant has a pipeline of late- and early-stage product candidates that focuses on the cognitive, functional, and behavioral aspects of debilitating conditions such as Alzheimer's disease and Lewy body dementia and other neurological disorders. For more information, visit www.axovant.com.